5 May 2005   
News
Executive Vice President's Message
Volunteer Focus
Press Releases
Standards Status
Notice of Vote and Deadlines
Newly Approved Documents
Newly Published ISO Standards
Call for Nominations
Terminology Focus
Events and Exhibits
Upcoming Events
Calendar of Meetings
Participation in CLSI
Volunteer
New and Sustaining Member List
Update Your Subscription
 
CLSI Home Page
Search Past Issues
Update Your Contact Information
Print this article Print all articles
 
Which type of documents do you prefer?
 

Detailed theory and applications

 

General theory and detailed procedures

 

Application-focused procedures

 

Basic at-a-glance procedures

 

Other




Standards Status

Notice of Vote and Deadlines
Sweat Testing: Sample Collection and Quantitative Analysis (C34-A2 -- Reaffirmation)

C34-A2Sweat Testing:  Sample Collection and Quantitative Analysis; Approved Guideline—Second Edition (Reaffirmation)

The "sweat test," a quantitative measurement of chloride in sweat, is used to confirm the diagnosis of cystic fibrosis, but has been reported to have uncacceptably high false-positive and false-negative rates.  These rates (up to 15% false-positive and 12% false-negative) are attributable to inaccurate methodology, technical error, and patient physiology.  This document provides much-needed comprehensive guidelines addressing the collection of sweat and the quantitative measurement of electrolytes in sweat are needed.

The deadline for the completed ballot for C34-A2 to be received int he CLSI Offices is 5 July 2005.

Reaffirmation of a CLSI document is appropriate when the area committee determines that neither comments received nor any other substantive reasons support changes.  As with other candidate-for-advancement documents, only delegates from Active and Associate Active member organizations may vote, using a ballot found on CLSI Forums.   


Second Notice

MM3-P2Molecular Diagnostic Methods for Infectious Diseases; Proposed Guideline--Second Edition

This guideline addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories. 

The deadline for the completed ballot for MM3-P2 to be received in the CLSI Offices is 11 July 2005.



Ballots are posted on the Forums section of our website, available to Active and Associate Active members.  Login to Forums to access the candidate-for-advancement forms, and send your completed ballot to the Executive Offices by the listed deadline. 

Not yet a voting member?  Find out more about
Active and Associate Active membership.

Under our Administrative Procedures, a CLSI document approved by the area committee at the first level of the consensus process is submitted to delegates as a “candidate-for-advancement” consensus document. This begins the voting and approval period by the delegates.

Remember that we welcome and encourage comments from our voting members at each publication stage.  Comments on a candidate-for-advancement consensus document will be addressed by the committee prior to advancement.  In each document edition, a summary of comments on the prior edition is included, along with committee responses.  [ return to top ]

For more information or to contact us directly, please visit www.clsi.org
©2005 Clinical and Laboratory Standards Institute